Fierce Pharma3d
J&J advances Stelara succession scheme with FDA nod for Tremfya in Crohn's disease
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
BioSpace2d
J&J Wins Crohn’s Expansion for Tremfya as Stelara Biosimilars Enter US Market
The label expansion couls help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
Hosted on MSN3mon
Celltrion's Crohn's treatment set for February U.S. release
Celltrion’s Steqeyma, a biosimilar that references Johnson & Johnson’s blockbuster monoclonal antibody Stelara, received approval from the U.S. Food and Drug Administration (FDA) to target ...
pharmaphorum1y
Stada, Alvotech get first EU approval for biosimilar Stelara
Johnson & Johnson’s blockbuster immunology drug Stelara is facing its first approved ... a biosimilar of the IL-12 and IL-23 inhibitor antibody developed by STADA and partner Alvotech ...